Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

Ryan C. Ungaro 1 Clara Yzet 2 Peter Bossuyt 3 Filip J. Baert 4 Thomas Vanasek Geert R. d'Haens 5 Vincent Wilhelmus Joustra 5 Remo Panaccione 6 Gottfried Novacek 7 Walter Reinisch 7 Alessandro Armuzzi 8, 9 Oleksandr Golovchenko Olga Prymak Adrian Goldis 10 Simon P. Travis 11 Xavier Hebuterne 12 Marc Ferrante 13 Gerhard Rogler 14 Mathurin Fumery 2, 15 Silvio Danese 16 Grazyna Rydzewska 17 Benjamin Pariente 18 Erik Hertervig 19 Carol Stanciu 20 Melanie Serrero 21 Mircea Diculescu 22 Laurent Peyrin-Biroulet 23, 24 David Laharie 25 John P. Wright Fernando Gomollon 26 Irina Gubonina Stefan Schreiber 27 Satoshi Motoya Per M. Hellstrom 28 Jonas Halfvarson 29 James W. Butler Joel Petersson 30 Francesca Petralia 1 Jean-Frederic Colombel 1 
Abstract : BACKGROUND & AIMS: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS: We collected follow-up data from 122 patients (mean age, 31.2 +/- 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS: Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P =.01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.070.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS: In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : mardi 1 février 2022 - 16:43:27
Dernière modification le : mardi 30 août 2022 - 10:56:20

Lien texte intégral



Ryan C. Ungaro, Clara Yzet, Peter Bossuyt, Filip J. Baert, Thomas Vanasek, et al.. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology, Elsevier, 2020, 159 (1), pp.139-147. ⟨10.1053/j.gastro.2020.03.039⟩. ⟨hal-03551527⟩



Consultations de la notice